Atul Dandekar Sells 3,191 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 3,191 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $26.47, for a total transaction of $84,465.77. Following the completion of the sale, the insider directly owned 35,559 shares of the company’s stock, valued at $941,246.73. This represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $84,350.43.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Trading Up 1.3%

Shares of MAZE stock opened at $26.21 on Friday. The business has a 50-day moving average of $28.69 and a 200 day moving average of $31.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics, Inc. has a 1-year low of $14.27 and a 1-year high of $53.65. The stock has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Institutional Trading of Maze Therapeutics

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Maze Therapeutics during the 1st quarter valued at $57,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth about $145,000. Rhumbline Advisers bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $80,000. Geode Capital Management LLC boosted its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the period.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analyst Ratings Changes

Several brokerages have weighed in on MAZE. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.